Evidence map›Paper›PMID 42250114›Full record

ArticleMikrochimica acta2026

Engineering a glycosyl-imprinted nanozyme with a dual-ligand Ce-MOF for the selective and sensitive colorimetric sensing of CA19-9.

Zhenghong Zhao, Yue Xu, Shuzhen Xu, Lianming Zhang, Jianping Li

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhenghong ZhaoCollege of Environmental Science and Engineering, Guilin University of technology, Guilin, Guangxi, 541004, China.
Yue XuCollege of Chemistry and Bioengineering, Guilin University of technology, Guilin, Guangxi, 541004, China.
Shuzhen XuCollege of Chemistry and Bioengineering, Guilin University of technology, Guilin, Guangxi, 541004, China.
Lianming ZhangCollege of Chemistry and Bioengineering, Guilin University of technology, Guilin, Guangxi, 541004, China.
Jianping LiCollege of Environmental Science and Engineering, Guilin University of technology, Guilin, Guangxi, 541004, China. likianping@263.net.

Funding

Scientific Research Startup Foundation of Guilin University of Technology GUTQDJJ2024060the National Natural Science Foundation of China No. 22264010, 22564010
6 · The paper itself

Abstract

The detection of carbohydrate antigen 19 - 9 (CA19-9), a critical serum marker for gastrointestinal malignancies, is particularly challenging because of its typically low concentration and substantial matrix interference, creating a critical demand for improved detection technologies. Herein, we rationally designed and synthesized a nanozyme with dual-ligand cerium-organic framework (Ce-MOF-BN) nanozyme for glycosyl-imprinted colorimetric biosensing via a one-pot method. The crystalline porous framework is densely functionalized on its surface with spatially accessible amino and boronic acid groups, enabling the recognition and oriented immobilization of imprinting templates. A well-defined core-shell molecularly imprinted composite was successfully fabricated through the systematic optimization of the ligand ratio. The composite exhibits intrinsic oxidase-like activity without requiring H

Indexed as

Biosensing TechniquesCA-19-9 AntigenColorimetryMetal-Organic FrameworksMolecular ImprintingAntigens, Tumor-Associated, CarbohydrateCeriumHumansLigandsLimit of DetectionAntigens, Tumor-Associated, CarbohydrateCA-19-9 AntigenCeriumLigandsMetal-Organic FrameworksColorimetric sensingCore-shell structureDual-ligandGlycosyl-imprintedMOF nanozyme

Identifiers

PMID42250114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.